Review of NICE Technology Appraisal Guidance No.23; Temozolomide for the treatment of recurrent malignant glioma, and No.121; Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma
Proposal to move the existing guidance to the ‘static guidance’ list – January 2016
The planned date for review of the above guidance is 2015.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
There is no new available evidence that is likely to lead to a change in the existing recommendations in TA121. Consequently we propose that TA121 should move to the ‘static guidance’ list.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
As temozolomide is now recommended for first-line treatment in TA121, recommendations 1.2 and 1.3 of TA23 are now out of date and should be withdrawn. Recommendation 1.1 of TA23 should remain, but the wording should be changed so as to match the current wording conventions used in NICE guidance. This newly worded recommendation should then move to the ‘static guidance’ list.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: